Premium
Preferential development of pre‐B lymphomas with drastically down‐regulated N‐myc in the Eμ‐ret transgenic mice
Author(s) -
Iwamoto Takashi,
Pu Meiyi,
Ito Masafumi,
Takahashi Masahide,
Isobe KenIchi,
Nagase Fumihiko,
Kawashima Kohei,
Ichihara Masatoshi,
Nakashima Izumi
Publication year - 1991
Publication title -
european journal of immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.272
H-Index - 201
eISSN - 1521-4141
pISSN - 0014-2980
DOI - 10.1002/eji.1830210805
Subject(s) - biology , enhancer , transgene , microbiology and biotechnology , genetically modified mouse , lymphoma , immunoglobulin heavy chain , b cell , complementary dna , gene , antibody , transfection , gene expression , cancer research , immunology , genetics
Abstract We established one transgenic mouse line which developed pre‐B leukemic lymphomas by introducing ret cDNA driven by the SV40 promoter and the mouse immunoglobulin (Ig) enhancer. Lymphomas developed not only in the lymph nodes and the spleen but also in the thymus between the ages of 7 and 21 weeks. Analyses of cell surface phenotypes and Ig gene rearrangement revealed that these tumors were surface IgM − B220 + pre‐B lymphomas. The rearrangement pattern of the Ig heavy chain locus indicated that the tumor cells were mono‐ or oligoclonal. Northern blot analysis showed that the ret transgene was expressed at a high level not only in the tumors but also in the prelymphomatous lymphoid tissues. We found that the expression of N‐myc was dramatically down‐regulated in the tumor cells, while the expression of c‐myc was rather stable. Further experiments demonstrated that ret gene product did not directly down‐regulate the expression of N‐myc in transformed pre‐B cell lines by in vitro transfection assay. From these results, we conclude that under the control of Ig enhancer, the ret transgene affected B lymphocytes at the early maturation stage as a prerequisite for transformation, preferentially generating a unique maturation stage of pre‐B lymphomas whose N‐myc expression was developmentally down‐regulated.